TerrAscend Corp. (TSNDF) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100.00%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced a loss of $0.03, delivering a surprise of -50%.Over the last four quarters, the company has surp ...

Insulet (PODD) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $0.9 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.73%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $0.93 per share when it actually produced earnings of $1.17, delivering a surprise of +25.81%.Over the last four quar ...

Core Insights - Flora Growth Corp. reported a quarterly loss of $4.93 per share, significantly worse than the Zacks Consensus Estimate of a loss of $2.13, marking an earnings surprise of -131.46% [1] - The company's revenues for the quarter ended September 2025 were $9.75 million, missing the Zacks Consensus Estimate by 22.14%, and down from $12.47 million a year ago [2] - Flora Growth shares have declined approximately 76.7% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Financial Performance - The company has not surpassed consensus EPS estimates over the last four quarters, indicating ongoing challenges in meeting market expectations [2] - The current consensus EPS estimate for the upcoming quarter is -$1.97 on revenues of $11.56 million, and for the current fiscal year, it is -$23.01 on revenues of $50.66 million [7] Market Outlook - The Zacks Rank for Flora Growth is currently 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] - The Medical - Products industry, to which Flora Growth belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may negatively impact stock performance [8]

Core Insights - Evolus, Inc. reported a quarterly loss of $0.14 per share, better than the Zacks Consensus Estimate of a loss of $0.19, marking an earnings surprise of +26.32% [1] - The company posted revenues of $68.97 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.70% and showing an increase from $61.08 million year-over-year [2] - Evolus shares have declined approximately 41.9% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Financial Performance - Over the last four quarters, Evolus has exceeded consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $91.18 million, while for the current fiscal year, it is -$0.48 on revenues of $297.1 million [7] Market Outlook - The company's earnings outlook and management's commentary during the earnings call will be crucial for future stock price movements [3][4] - The Zacks Rank for Evolus is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Products industry, to which Evolus belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may impact stock performance [8] - Comparatively, ICU Medical, another company in the same industry, is expected to report a quarterly earnings decline of -3.1% year-over-year [9]

biote Corp. (BTMD) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +340.00%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.1, delivering a surprise of +66.67%.Over the last four quarters, the company ha ...

Company Performance - Zimmer Biomet reported quarterly earnings of $1.9 per share, exceeding the Zacks Consensus Estimate of $1.88 per share, and up from $1.74 per share a year ago, representing an earnings surprise of +1.06% [1] - The company posted revenues of $2 billion for the quarter ended September 2025, which was below the Zacks Consensus Estimate by 0.42%, but an increase from $1.82 billion year-over-year [2] - Over the last four quarters, Zimmer has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Outlook - Zimmer shares have declined approximately 2.3% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.39 on revenues of $2.23 billion, and for the current fiscal year, it is $8.15 on revenues of $8.22 billion [7] Industry Context - The Medical - Products industry, to which Zimmer belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5][6]

Group 1 - CeriBell, Inc. reported a quarterly loss of $0.37 per share, better than the Zacks Consensus Estimate of a loss of $0.43, and an improvement from a loss of $1.85 per share a year ago, resulting in an earnings surprise of +13.95% [1] - The company posted revenues of $22.59 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.65%, and showing an increase from $17.19 million in the same quarter last year [2] - CeriBell, Inc. has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times in the same period [2] Group 2 - The stock has underperformed, losing about 56.2% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $23.33 million, and for the current fiscal year, it is -$1.55 on revenues of $86.82 million [7] - The Zacks Industry Rank for Medical - Products is in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - Exagen Inc. reported a quarterly loss of $0.19 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, representing an earnings surprise of -46.15% [1] - The company achieved revenues of $17.24 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 0.55% and showing a year-over-year increase from $12.51 million [2] - Exagen shares have increased approximately 188.5% year-to-date, significantly outperforming the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Exagen has surpassed consensus revenue estimates four times, but only exceeded EPS estimates once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $18.03 million, and for the current fiscal year, it is -$0.66 on revenues of $67.65 million [7] Industry Context - The Medical - Products industry, to which Exagen belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Exagen's stock may be influenced by the overall outlook of the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Future Outlook - The sustainability of Exagen's stock price movement will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The estimate revisions trend for Exagen was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]

分组1 - AdaptHealth Corp. reported quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.24 per share, representing an earnings surprise of -8.33% [1] - The company posted revenues of $820.31 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.34%, compared to year-ago revenues of $805.86 million [2] - Over the last four quarters, AdaptHealth has surpassed consensus revenue estimates three times, but has only exceeded EPS estimates once [2] 分组2 - The stock has underperformed the market, losing about 4.5% since the beginning of the year, while the S&P 500 gained 16.5% [3] - The current consensus EPS estimate for the coming quarter is $0.45 on revenues of $851.47 million, and for the current fiscal year, it is $0.85 on revenues of $3.23 billion [7] - The Zacks Industry Rank for Medical - Products is currently in the bottom 41% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8]

Core Insights - InfuSystems Holdings, Inc. reported quarterly earnings of $0.11 per share, exceeding the Zacks Consensus Estimate of $0.08 per share, and showing an increase from $0.08 per share a year ago, resulting in an earnings surprise of +37.50% [1] - The company posted revenues of $36.49 million for the quarter ended September 2025, which was 1.91% below the Zacks Consensus Estimate, but an increase from $35.32 million year-over-year [2] - InfuSystems Holdings has outperformed the S&P 500 with a 23.1% gain since the beginning of the year compared to the S&P 500's 16.5% gain [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $36.25 million, and for the current fiscal year, it is $0.26 on revenues of $144.15 million [7] - The estimate revisions trend for InfuSystems Holdings was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Products industry, to which InfuSystems belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of InfuSystems Holdings may be influenced by the overall outlook of the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]